# Pazopanib in Second-line Therapy in Renal Cell Carcinoma

> **NCT01577784** · PHASE2 · UNKNOWN · sponsor: **Associació per a la Recerca Oncologica, Spain** · enrollment: 27 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01577784
- **Lead sponsor:** Associació per a la Recerca Oncologica, Spain
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-04
- **Primary completion:** 2014-10
- **Final completion:** 2015-10
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2014-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01577784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01577784, "Pazopanib in Second-line Therapy in Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01577784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*